Lymphocyte Predominant Hodgkin Lymphoma

This chapter contains sections titled: Introduction Questions Literature‐search strategy and inclusions Is LPHL a distinct clinical/pathologic entity from classical HL? Should de novo LPHL be treated differently from classical Hodgkin lymphoma? Should detection and treatment of LPHL progression or relapse be different from classical Hodgkin lymphoma? Should rituximab be included as “standard” therapeutic modality for LPHL? Recommendation …